No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

in StudyGraphics

RELATED REPORTS

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

RelatedReports

Lessons from real-world implementation of lung cancer screening

AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025

New genetic link in pulmonary arterial hypertension holds therapeutic promise

Chronic Disease

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

June 2, 2025

AI Roundup

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

May 28, 2025

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result